

**EXHIBIT A**

Medical Center	Georgetown	Auxilio Mutuo	Lifelink Hlthcare Inst.	St. Anthony Hospital	Loma Linda UMC	UMCTucson	Dallas Neph. Assoc.	UH Case MC	St. Vincent MC	U of Washington MC	U of Michigan MC	UCLA	NY Presbyterian	U of Maryland MC	Northwestern	Mayo Clinic	% Yes	% No	# Yes	# No
HLA X Match	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
ABO X Match	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
CBC	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
UA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
Urine Prot to Creatine	Yes	No	Yes	No	Yes	No	Yes	Yes	No	No	No	No	No	Yes	Yes	Yes	50%	50%	8	8
Urine Culture	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	75%	25%	12	4
24H Urine	Yes	Yes	No	Yes	No	Yes	Yes	No	Yes	Yes	No	Yes	No	No	Yes	Yes	63%	38%	10	6
Micro-albumin	No	No	Yes	No	Yes	Yes	No	Yes	Yes	Yes	No	No	No	Yes	No	Yes	50%	50%	8	8
Fasting BS	Yes	Yes	No	No	Yes	No	No	Yes	Yes	Yes	No	No	No	Yes	No	Yes	50%	50%	8	8
Fasting lipid	No	Yes	No	No	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	No	56%	44%	9	7
OGTT	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	Yes	75%	25%	12	4
CMP	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	81%	19%	13	3
Cholesterol	No	Yes	Yes	No	No	No	No	No	Yes	No	Yes	No	Yes	No	No	Yes	38%	63%	6	10
Uric Acid	No	Yes	Yes	No	No	No	No	Yes	Yes	No	Yes	No	Yes	No	No	Yes	44%	56%	7	9
HIV	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
CMV IgG	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
EBV IgG	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes	No	Yes	75%	25%	12	4
RPR (VDRI)	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	88%	13%	14	2
HBCab/HBsAb	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	88%	13%	14	2
HBsAg	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	94%	6%	15	1
HCV or HCAB	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
IVP	No	Yes	No	No	No	No	No	Yes	No	No	Yes	Yes	No	No	No	No	25%	75%	4	12
PT/PTT	Yes	Yes	Yes	No	No	No	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	69%	31%	11	5
hCG	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	Yes	No	No	Yes	Yes	No	Yes	63%	38%	10	6
PAP	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	81%	19%	13	3
PPD	No	Yes	No	No	Yes	No	Yes	No	No	Yes	No	No	No	No	No	No	25%	75%	4	12
CXR	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
EKG	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
PSA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
Mammogram	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	75%	25%	12	4
Colonoscopy	No	No	Yes	No	No	No	Yes	No	No	Yes	No	Yes	Yes	No	No	Yes	38%	63%	6	10
ETT	No	No	Yes	No	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No	25%	75%	4	12
Toxicology	Yes	No	No	Yes	No	No	No	Yes	No	No	No	No	No	No	No	No	19%	81%	3	13
HBA1C	Yes	No	No	No	No	No	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No	No	44%	56%	7	9
ECHO	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No	13%	88%	2	14
MR Angiogram	Yes	No	No	No	No	No	Yes	Yes	No	Yes	No	No	Yes	No	No	Yes	38%	63%	6	10
Spiral CT	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	88%	13%	14	2
Ab Duplex	No	Yes	No	Yes	No	No	No	Yes	No	No	No	No	No	No	No	No	19%	81%	3	13
Angiogram	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No	Yes	Yes	25%	75%	4	12
Social Work	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	94%	6%	15	1
Psychiatry	No	Yes	No	Yes	No	Yes	Yes	No	No	No	No	Yes	Yes	No	Yes	Yes	50%	50%	8	8
Nephrology	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0
RN Coordinator	No	No	No	No	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	56%	44%	9	7
Surgeon	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	100%	0%	16	0

**Reference List for the Medical Evaluation of Living Kidney Donors****PSYCHOLOGICAL EVALUATION**

Dew MA, Jacobs CL, Jowsey SG, Hanto R, Miller C, Delmonico FL. Guidelines for the psychosocial evaluation of living unrelated kidney donors in the United States. *Am J Transplant.* 2007 May;7(5):1047-54.

Clemens KK, Thiessen-Philbrook H, Parikh CR, Yang RC, Karley ML, Boudville N, Ramesh Prasad GV, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network. Psychosocial health of living kidney donors: a systematic review. *Am J Transplant.* 2006 Dec;6(12):2965-77.

Rudow DL, Brown RS Jr. Role of the independent donor advocacy team in ethical decision making. *Prog Transplant.* 2005 Sep;15(3):298-302.

Rudow DL, Chariton M, Sanchez C, Chang S, Serur D, Brown RS Jr. Kidney and liver living donors: a comparison of experiences. *Prog Transplant.* 2005 Jun;15(2):185-91.

**SURGICAL RISK**

Matas AJ, Bartlett ST, Leichtman AB, Delmonico FL. Morbidity and mortality after living kidney donation, 1999-2001: survey of United States transplant centers. *Am J Transplant.* 2003 Jul;3(7):830-4.

Schweitzer EJ, Wilson J, Jacobs S, Machan CH, Philosophe B, Farney A, Colonna J, Jarrell BE, Bartlett ST. Increased rates of donation with laparoscopic donor nephrectomy. *Ann Surg* 2000 Sep;232(3):392-400.

Ratner, L.E., R.A. Montgomery, and L.R. Kavoussi, Laparoscopic live donor nephrectomy. A review of the first 5 years. *Urol Clin North Am*, 2001. 28(4):709-719.

Simon SD, Castle EP, Ferrigni RG, Lamm DL, Swanson SK, Novicki DE, Andrews PE. Complications of laparoscopic nephrectomy: the Mayo clinic experience. *J Urol* 2004 Apr;171(4):1447-50.

Jacobs SC, Cho E, Foster C, Liao P, Bartlett ST. Laparoscopic donor nephrectomy: the University of Maryland 6-year experience. *J Urol* 2004 Jan;171(1):47-51.

Su LM, Ratner LE, Montgomery RA, Jarrett TW, Trock BJ, Sinkov V, Bluebond-Langner R, Kavoussi LR. Laparoscopic live donor nephrectomy: trends in donor and recipient morbidity following 381 consecutive cases. *Ann Surg*, 2004. 240(2):358-363.

Chin EH, Hazzan D, Herron DM, Gaetano JN, Ames SA, Bromberg JS, Edye M. Laparoscopic donor nephrectomy: intraoperative safety, immediate morbidity, and delayed complications with 500 cases. *Surg Endosc.* 2007 Apr;21(4):521-6.

Bargman V, Sundaram CP, Bernie J, Goggins W. Randomized trial of laparoscopic donor nephrectomy with and without hand assistance. *J Endourol.* 2006 Oct;20(10):717-22.

Ruszat R, Sulser T, Dickenmann M, Wolff T, Gurke L, Eugster T, Langer I, Vogelbach P, Steiger J, Gasser TC, Stief CG, Bachmann A Retroperitoneoscopic donor nephrectomy: donor outcome and complication rate in comparison with three different techniques. *World J Urol.* 2006 Feb;24(1):113-7. Epub 2006 Jan 25

#### RISK OF END STAGE RENAL DISEASE

Ellison MD, McBride MA, Taranto SE, Delmonico FL, Kauffman HM. Living kidney donors in need of kidney transplants: a report from the organ procurement and transplantation network. *Transplantation.* 2002 Nov 15;74(9):1349-51.

Fehrman-Ekholm I, Norden G, Lennerling A, Rizell M, Mjornstedt L, Wramner L, Olausson M. Incidence of end-stage renal disease among live kidney donors. *Transplantation.* 2006 Dec 27;82(12):1646-8.

#### GENERAL EVALUATION GUIDELINES

Delmonico F; Council of the Transplantation Society. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: Data and Medical Guidelines. *Transplantation.* 2005 Mar 27;79(6 Suppl):S53-66.

Barr ML, Belghiti J, Villamil FG, Pomfret EA, Sutherland DS, Gruessner RW, Langnas AN, Delmonico FL. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. *Transplantation.* 2006 May 27;81(10):1373-85.

Kasiske BL, Ravenscraft M, Ramos EL, Gaston RS, Bia MJ, Danovitch GM. The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. *J Am Soc Nephrol.* 1996 Nov;7(11):2288-313.

Bia MJ, Ramos EL, Danovitch GM, Gaston RS, Harmon WE, Leichtman AB, Lundin PA, Neylan J, Kasiske BL. Evaluation of living renal donors. The current practice of US transplant centers. *Transplantation.* 1995 Aug 27;60(4):322-7

Gabolde M, Herve C, Moulin AM. Evaluation, selection, and follow-up of live kidney donors: a review of current practice in French renal transplant centres. *Nephrol Dial Transplant* 2001 Oct;16(10):2048-52.

Davis CL, Delmonico FL. Living-donor kidney transplantation: a review of the current practices for the live donor. *J Am Soc Nephrol.* 2005 Jul;16(7):2098-110.

Fehrman-Ekholm I, Gabel H, Magnusson G. Reasons for not accepting living kidney donors. *Transplantation.* 1996 Apr 27;61(8):1264-5

Koller H, Mayer G. Evaluation of the living kidney donor. *Nephrol Dial Transplant.* 2004 Jul;19 Suppl 4:iv41-4.

Steiner RW, Gert B. A technique for presenting risk and outcome data to potential living renal transplant donors. *Transplantation* 2001 Apr 27;71(8):1056-7.

Mandelbrot D, Pavlakis, M, Danovitch G, Johnson, S, Karp S, Khwaja K, Rodrique J. The medical

evaluation of living kidney donors: a survey of US transplant centers. *Am J Transplant* 2007. In press.

#### POST TRANSPLANT PSYCHOSOCIAL ISSUES/STUDIES

McCune TR, Armata T, Mendez-Picon G, Yium J, Zabari GB, Crandall B, Spicer HG, Blanton J, Thacker LR. The Living Organ Donor Network: a model registry for living kidney donors. *Clin Transplant*. 2004;18 Suppl 12:33-8.

Prager LM, Wain JC, Roberts DH, Ginns LC. Medical and psychologic outcome of living lobar lung transplant donors. *J Heart Lung Transplant*. 2006 Oct;25(10):1206-12.

Smith GC, Trauer T, Kerr PG, Chadban SJ. Prospective psychosocial monitoring of living kidney donors using the Short Form-36 health survey: results at 12 months. *Transplantation*. 2004 Nov 15;78(9):1384-9.

Boulware LE, Ratner LE, Troll MU, Chaudron A, Yeung E, Chen S, Klein AS, Hiller J, Powe NR. Attitudes, psychology, and risk taking of potential live kidney donors: strangers, relatives, and the general public. *Am J Transplant* 2005 Jul;5(7):1671-80.

Heck G, Schweitzer J, Seidel-Wiesel M. Psychological effects of living related kidney transplantation - risks and chances. *Clin Transplant*. 2004 Dec;18(6):716-21.

Tanriverdi N, Ozcurumez G, Colak T, Duru C, Emiroglu R, Zileli L, Haberal M. Quality of life and mood in renal transplantation recipients, donors, and controls: preliminary report. *Transplant Proc*. 2004 Jan-Feb;36(1):117-9

Lima DX, Petroianu A, Hauter HL. Quality of life and surgical complications of kidney donors in the late post-operative period in Brazil. *Nephrol Dial Transplant*. 2006 Nov;21(11):3238-42. Epub 2006 Aug 1

Dahm F, Weber M, Muller B, Pradel FG, Laube GF, Neuhaus TJ, Cao C, Wuthrich RP, Thiel GT, Clavien PA. Open and laparoscopic living donor nephrectomy in Switzerland: a retrospective assessment of clinical outcomes and the motivation to donate. *Nephrol Dial Transplant*. 2006 Sep;21(9):2563-8. Epub 2006 May 15

#### ABO/CROSSMATCHING

Schwartz J, Stegall MD, Kremers WK, Gloor J. Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation. *Transplantation*. 2006 Jul 27;82(2):155-63.

Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, DeGoey SR, Lager DJ, Grande JP, Stegall MD. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. *Am J Transplant*. 2006 Aug;6(8):1841-7.

Ishida H, Tanabe K, Ishizuka T, Furusawa M, Miyamoto N, Ishikawa N, Shirakawa H, Shimmura H, Ishii D, Nozaki D, Setoguchi K, Toma H. Differences in humoral immunity between a non-rejection group and a rejection group after ABO-incompatible renal transplantation. *Transplantation*. 2006 Mar 15;81(5):665-71.

Starzl TE, Tzakis A, Makowka L, Banner B, Demetrius A, Ramsey G, Duquesnoy R, Griffin M. The definition of ABO factors in transplantation: relation to other humoral antibody states. *Transplant Proc*.

1987 Dec;19(6):4492-7.

Wen R, Wu V, Dmitrienko S, Yu A, Balshaw R, Keown PA; Genome Canada Biomarkers in Transplantation Group. Biomarkers in transplantation: Prospective, blinded measurement of predictive value for the flow cytometry crossmatch after negative antiglobulin crossmatch in kidney transplantation. *Kidney Int.* 2006 Oct;70(8):1474-81.

Ishida H, Tanabe K, Furusawa M, Ishizuka T, Hayashi T, Tokumoto T, Miyamoto N, Shirakawa H, Shimmura H, Shimizu T, Toma H. Evaluation of flow cytometric panel reactive antibody in renal transplant recipients - examination of 238 cases of renal transplantation. *Transpl Int.* 2005 Feb;18(2):163-8.

El Fettouh HA, Cook DJ, Bishay E, Flechner S, Goldfarb D, Modlin C, Dennis V, Novick AC. Association between a positive flow cytometry crossmatch and the development of chronic rejection in primary renal transplantation. *Urology.* 2000 Sep 1;56(3):369-72.

O'Rourke RW, Osorio RW, Freise CE, Lou CD, Garovoy MR, Bacchetti P, Ascher NL, Melzer JS, Roberts JP, Stock PG. Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. *Clin Transplant.* 2000 Apr;14(2):167-73.

#### GESTATIONAL DIABETES; RISK FOR TYPE II DIABETES

Lee AJ, Hiscock RJ, Wein P, Walker SP, Permezel M. Gestational diabetes mellitus: clinical predictors and long-term risk of developing type 2 diabetes: a retrospective cohort study using survival analysis. *Diabetes Care.* 2007 Apr;30(4):878-83.

Retnakaran R, Connelly PW, Maguire G, Sermer M, Zinman B, Hanley AJ. Decreased high-molecular-weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes. *Diabet Med* 2007 Mar;24(3):245-52.

Lim S, Choi SH, Park YJ, Park KS, Lee HK, Jang HC, Cho NH, Metzger BE. Visceral fatness and insulin sensitivity in women with a previous history of gestational diabetes mellitus. *Diabetes Care* 2007 Feb;30(2):348-53.

Yun S, Kabeer NH, Zhu BP, Brownson RC. Modifiable risk factors for developing diabetes among women with previous gestational diabetes. *Prev Chronic Dis.* 2007 Jan;4(1):A07.

Hussain A, Claussen B, Ramachandran A, Williams R. Prevention of type 2 diabetes: a review. *Diabetes Res Clin Pract* 2007 Jun;76(3):317-26.

Case J, Willoughby D, Haley-Zitlin V, Maybee P. Preventing type 2 diabetes after gestational diabetes. *Diabetes Educ.* 2006 Nov-Dec;32(6):877-86.

Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. *Diabetes Care.* 2007 Jan;30(1):38-42.

Thamer C, Machann J, Stefan N, Haap M, Schafer S, Brenner S, Kantartzis K, Claussen C, Schick F, Haring H, et al. High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. *Obesity (Silver Spring)* 2007 Feb;15(2):531-8.

Diamantopoulos EJ, Andreadis EA, Tsourous GI, Ifanti GK, Katsanou PM, Georgiopoulos DX, Vassilopoulos CV, Dimitriadis G, Raptis SA. Metabolic syndrome and prediabetes identify overlapping but not identical populations. *Exp Clin Endocrinol Diabetes* 2006 Jul;114(7):377-83.

Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA.

Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. *Diabetes*. 2006 May;55(5):1430-5.

Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? *Diabetes Care* 2007 Jun;30(6):1544-8.

Dankner R, Abdul-Ghani MA, Gerber Y, Chetrit A, Wainstein J, Raz I. Predicting the 20-year diabetes incidence rate. *Diabetes Metab Res Rev*. 2007 Feb 21

Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Utility of hemoglobin A1c in predicting diabetes risk. *J Gen Intern Med*. 2004 Dec;19(12):1175-80.

#### NONSTEROIDAL MEDICATIONS AND RENAL RISK

Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR. NSAID use and progression of chronic kidney disease. *Am J Med*. 2007 Mar;120(3):280.e1-7.

Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. *Am J Epidemiol*. 2006 Nov 1;164(9):881-9. Epub 2006 Sep 27.

Ibanez L, Morlans M, Vidal X, Martinez MJ, Laporte JR. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. *Kidney Int* 2005 Jun;67(6):2393-8.

Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. *Am J Kidney Dis*. 2005 Mar;45(3):531-9.

#### ILLCIT DRUGS AND RENAL FAILURE

Gitman MD, Singhal PC. Cocaine-induced renal disease. *Expert Opin Drug Saf* 2004 Sep;3(5):441-8.

Norris KC, Thornhill-Joynes M, Robinson C, Strickland T, Alperson BL, Witana SC, Ward HJ. Cocaine use, hypertension, and end-stage renal disease. *Am J Kidney Dis* 2001 Sep;38(3):523-8.

Norris KC, Thornhill-Joynes M, Tareen N. Cocaine use and chronic renal failure. *Semin Nephrol*. 2001 Jul;21(4):362-6.

Bakir AA, Dunea G. Renal disease in the inner city. *Semin Nephrol* 2001 Jul;21(4):334-45.

#### LONG-TERM DONOR RISK

Sundaram CP, Martin GL, Guise A, Bernie J, Bargman V, Milgrom M, Shalhav A, Govani M, Goggins W. Complications after a 5-year experience with laparoscopic donor nephrectomy: the Indiana University experience. *Surg Endosc.* 2007 May;21(5):724-8.

Fehrman-Ekholm I, Elinder CG, Stenbeck M, Tyden G, Groth CG. Kidney donors live longer. *Transplantation.* 1997 Oct 15;64(7):976-8.

Fehrman-Ekholm I, Johansson A, Konberg A, Tyden G. Long-term survival of living related kidney donors. *Transplant Proc.* 1997 Feb-Mar;29(1-2):1481.

Fehrman-Ekholm I, Duner F, Brink B, Tyden G, Elinder CG. No evidence of accelerated loss of kidney function in living kidney donors: results from a cross-sectional follow-up. *Transplantation.* 2001 Aug 15;72(3):444-9.

Fehrman-Ekholm I, Brink B, Ericsson C, Elinder CG, Duner F, Lundgren G. Kidney donors don't regret: follow-up of 370 donors in Stockholm since 1964. *Transplantation* 2000 May 27;69(10):2067-71.

Kasiske BL, Ma JZ, Louis TA, Swan SK. Long-term effects of reduced renal mass in humans. *Kidney Int.* 1995 Sep;48(3):814-9.

Jacobs CL, Roman D, Garvey C, Kahn J, Matas AJ. Twenty-two nondirected kidney donors: an update on a single center's experience. *Am J Transplant* 2004 Jul;4(7):1110-6.

Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of follow-up of living kidney donors. *Lancet* 1992 Oct 3;340(8823):807-10.

Narkun-Burgess DM, Nolan CR, Norman JE, Page WF, Miller PL, Meyer TW. Forty-five year follow-up after uninephrectomy. *Kidney Int* 1993 May;43(5):1110-5.

Ramcharan T, Matas AJ. Long-term (20-37 years) follow-up of living kidney donors. *Am J Transplant* 2002 Nov;2(10):959-64.

Ellison MD, McBride MA, Taranto SE, Delmonico FL, Kauffman HM. Living kidney donors in need of kidney transplants: a report from the organ procurement and transplantation network. *Transplantation* 2002 Nov 15;74(9):1349-51.

Demir E, Balal M, Paydas S, Sertdemir Y, Erken U. Dyslipidemia and weight gain secondary to lifestyle changes in living renal transplant donors. *Transplant Proc.* 2005 Dec;37(10):4176-9.

#### HEMATURIA

Koushik R, Garvey C, Manivel JC, Matas AJ, Kasiske BL. Persistent, asymptomatic, microscopic hematuria in prospective kidney donors. *Transplantation.* 2005 Nov 27;80(10):1425-9.

Ierino FL, Kanellis J. Thin basement membrane nephropathy and renal transplantation. *Semin Nephrol* 2005 May;25(3):184-7.

Iseki K. The okinawa screening program. *J Am Soc Nephrol* 2003 Jul;14(7 Suppl 2):S127-30.

Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. *Kidney Int* 1996 Mar;49(3):800-5.

Dische FE. Measurement of glomerular basement membrane thickness and its application to the diagnosis of thin-membrane nephropathy. *Arch Pathol Lab Med* 1992 Jan;116(1):43-9.

Dische FE, Anderson VE, Keane SJ, Taube D, Bewick M, Parsons V. Incidence of thin membrane nephropathy: morphometric investigation of a population sample. *J Clin Pathol* 1990 Jun;43(6):457-60.

Dische FE, Weston MJ, Parsons V. Abnormally thin glomerular basement membranes associated with hematuria, proteinuria or renal failure in adults. *Am J Nephrol* 1985;5(2):103-9.

Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. *N Engl J Med* 2003 Jun 19;348(25):2543-56.

Lemmink HH, Schroder CH, Monnens LA, Smeets HJ. The clinical spectrum of type IV collagen mutations. *Hum Mutat* 1997;9(6):477-99.

Jalalah SM, Alzahrani IH, Furness PN. Glomerular changes in microscopic haematuria, studied by quantitative immunoelectron microscopy and in situ zymography. *Nephrol Dial Transplant* 2002 Sep;17(9):1586-93.

Nieuwhof CM, de Heer F, de Leeuw P, van Breda Vriesman PJ. Thin GBM nephropathy: premature glomerular obsolescence is associated with hypertension and late onset renal failure. *Kidney Int* 1997 May;51(5):1596-601.

Gandhi S, Kalantar-Zadeh K, Don BR. Thin-glomerular-basement-membrane nephropathy: is it a benign cause of isolated hematuria? *South Med J* 2002 Jul;95(7):768-71.

Liapis H, Gokden N, Hmiel P, Miner JH. Histopathology, ultrastructure, and clinical phenotypes in thin glomerular basement membrane disease variants. *Hum Pathol* 2002 Aug;33(8):836-45.

Piel CF, Biava CG, Goodman JR. Glomerular basement membrane attenuation in familial nephritis and "benign" hematuria. *J Pediatr* 1982 Sep;101(3):358-65.

Tonna S, Wang YY, MacGregor D, Sinclair R, Martinello P, Power D, Savige J. The risks of thin basement membrane nephropathy. *Semin Nephrol* 2005 May;25(3):171-5.

Szeto CC, To KF, Lai FM, Chow KM, Tam WH, Chung KY, Leung CB, Lui SF, Li PK, Lau TK. Prevalence and implications of isolated microscopic hematuria in asymptomatic Chinese pregnant women. *Nephron Clin Pract.* 2007;105(4):c147-52.

Rana K, Wang YY, Buzza M, Tonna S, Zhang KW, Lin T, Sin L, Padavarat S, Savige J. The genetics of thin basement membrane nephropathy. *Semin Nephrol.* 2005 May;25(3):163-70.

Gregory MC. The clinical features of thin basement membrane nephropathy. *Semin Nephrol* 2005 May;25(3):140-5.

#### HEMATURIA – NEPHROLITHIASIS

Lee YH, Huang WC, Chang LS, Chen MT, Yang YF, Huang JK. The long-term stone recurrence rate and

renal function change in unilateral nephrectomy urolithiasis patients. *J Urol.* 1994 Nov;152(5 Pt 1):1386-8.

Sarica K, Kohle R, Kunit G, Frick J. Experiences with extracorporeal shock wave lithotripsy in patients with a solitary kidney. *Urol Int.* 1992;48(2):200-2.

Worcester EM, Parks JH, Evan AP, Coe FL. Renal function in patients with nephrolithiasis. *J Urol.* 2006 Aug;176(2):600-3.

Gillen DL, Worcester EM, Coe FL. Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. *Kidney Int.* 2005 Feb;67(2):685-90.

Worcester E, Parks JH, Josephson MA, Thisted RA, Coe FL. Causes and consequences of kidney loss in patients with nephrolithiasis. *Kidney Int.* 2003 Dec;64(6):2204-13.

#### POLYCYSTIC KIDNEY DISEASE DETECTION

Nicolau C, Torra R, Badenas C, et al. Autosomal dominant polycystic kidney disease type 1 and 2: Assessment of US sensitivity for diagnosis. *Radiology* 1999;213:273-6.

Zand MS, Strang J, Dumlao M, Rubens D, Erturk E, Bronsther O. Screening a living kidney donor for polycystic kidney disease using heavily T2 weighted MRI. *Am J Kidney Dis* 2001;37(2):612-9.

Cassart M, Massez A, Metens T, et al. Complementary role of MRI after sonography in assessing bilateral urinary tract anomalies in the fetus. *AJR Am J Roentgenol* 2004;182(3):689-95.

Rossetti S, Chauveau D, Walker D, et al. A complete mutation screen of the ADPKD genes by DHPLC. *Kidney Int* 2002;61(5):1588-99.

Rossetti S, Chauveau D, Kubly V, et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. *Lancet* 2003;361(9376):2196-201.

Rossetti S, Torra R, Coto E, et al. A complete mutation screen of PKHD1 in autosomal-recessive polycystic kidney disease (ARPKD) pedigrees. *Kidney Int* 2003;64(2):391-403.

Magistroni R, He N, Wang K, et al. Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 2003;14(5):1164-74.

Phakdeekitcharoen B, Watnick TJ, Germino GG. Mutation analysis of the entire replicated portion of PKD1 using genomic DNA samples. *J Am Soc Nephrol* 2001;12(5):955-63.

Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Dobin A, Gabow PA. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 1995;5(12):2032-6.

Hossack KF, Leddy CL, Johnson AM, Schrier RW, Gabow PA. Echocardiographic findings in autosomal dominant polycystic kidney disease. *N Engl J Med* 1988;319(14):907-12.

Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. *Lancet.* 2007 Apr 14;369(9569):1287-301.

Bisceglia M, Galliani CA, Senger C, Stallone C, Sessa A. Renal cystic diseases: a review. *Adv Anat Pathol.* 2006 Jan;13(1):26-56.

Binczak-Kuleta A, Rozanski J, Domanski L, Myslak M, Ciechanowski K, Ciechanowicz A. DNA microsatellite analysis in families with autosomal dominant polycystic kidney disease (ADPKD): the first Polish study. *J Appl Genet.* 2006;47(4):383-9.

Bae Y, Kim H, Paik M, Lee J, Hwang D, Hwang Y, Ahn C, Kang S. Characterization of microsatellite markers to diagnose ADPKD. *Mol Cell Probes.* 2004 Jun;18(3):155-9.

## HYPERTENSION

Toto RD. Lessons from the African-American Study of Kidney Disease and Hypertension: an update. *Curr Hypertens Rep.* 2006 Oct;8(5):409-12.

Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LJ. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. *J Am Soc Nephrol.* 2006 Oct;17(10):2928-36.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glasscock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA.* 2002 Nov 20;288(19):2421-31.

Textor SC, Taler SJ, Driscoll N, Larson TS, Gloor J, Griffin M, Cosio F, Schwab T, Prieto M, Nyberg S, Ishitani M, Stegall M. Blood pressure and renal function after kidney donation from hypertensive living donors. *Transplantation.* 2004 Jul 27;78(2):276-82.

Goto N, Uchida K, Morozumi K, Ueki T, Matsuoka S, Katayama A, Haba T, Tominaga Y, Fukuda M, Nakao A, Kimura G. Circadian blood pressure rhythm is disturbed by nephrectomy. *Hypertens Res.* 2005 Apr;28(4):301-6.

Ito K, Nakashima J, Hanawa Y, Oya M, Ohigashi T, Marumo K, Murai M. The prediction of renal function 6 years after unilateral nephrectomy using preoperative risk factors. *J Urol.* 2004 Jan;171(1):120-5.

Ozdemir, N., et al., Ambulatory blood pressure monitoring in potential renal transplant donors. *Transplant Proc.* 1999. 31(8):3369-70.

Textor, S.C., et al., Blood pressure evaluation among older living kidney donors. *J Am Soc Nephrol.* 2003. 14:2159-2167.

Textor, S.C., et al., Blood pressure and renal function after kidney donation from hypertensive living donors. *Transplantation.* 2004. 78(2):276-282.

Torres, V.E., et al., Blood pressure determinants in living-related renal allograft donors and their recipients. *Kidney Int.* 1987. 31(6):1383-90.

MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE

Rosinol L, Cibeira MT, Montoto S, Rozman M, Esteve J, Filella X, Blade J. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size.

Mayo Clin Proc. 2007 Apr;82(4):428-34.

Bergon E, Miravalles E. Retrospective study of monoclonal gammopathies detected in the clinical laboratory of a Spanish healthcare district: 14-year series. Clin Chem Lab Med. 2007;45(2):190-6.

Khan MM, Mori M, Sakauchi F, Matsuo K, Ozasa K, Tamakoshi A; JACC Study group. Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):575-81.

Maisnar V, Tichy M, Rehacek V, Palicka V, Maly J. Monoclonal gammopathies in a series of 1743 plasma donors. Acta Medica (Hradec Kralove). 2006;49(2):119-21.

Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer. 2006 Jul;42(11):1671-83.

Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006 Mar 30;354(13):1362-9.

PRE-OPERATIVE EVALUATION – SMOKING

Warner DO. Tobacco dependence in surgical patients. Curr Opin Anaesthesiol. 2007 Jun;20(3):279-83.

Lawrence VA, Cornell JE, Smetana GW; American College of Physicians. Strategies to reduce postoperative pulmonary complications after noncardiothoracic surgery: systematic review for the American College of Physicians. Ann Intern Med. 2006 Apr 18;144(8):596-608. Review. Summary for patients in: Ann Intern Med. 2006 Apr 18;144(8):140.

PREOPERATIVE EVALUATION CARDIAC EXAMINATION/TESTING

Cohn SL. Cardiac risk stratification before noncardiac surgery. Cleve Clin J Med. 2006 Mar;73 Suppl 1:S18-24. Review

Gordon AJ, Macpherson DS. Guideline chaos: conflicting recommendations for preoperative cardiac assessment. Am J Cardiol. 2003 Jun 1;91(11):1299-303.

Barak M, Ben-Abraham R, Katz Y. ACC/AHA guidelines for preoperative cardiovascular evaluation for noncardiac surgery: a critical point of view. Clin Cardiol. 2006 May;29(5):195-8.

Falcone RA, Nass C, Jermyn R, Hale CM, Stierer T, Jones CE, Walters GK, Fleisher LA. The value of preoperative pharmacologic stress testing before vascular surgery using ACC/AHA guidelines: a prospective, randomized trial. J Cardiothorac Vasc Anesth. 2003 Dec;17(6):694-8.

Almanaseer Y, Mukherjee D, Kline-Rogers EM, Kesterson SK, Sonnad SS, Rogers B, Smith D, Furney

S, Ernst R, McCort J, Eagle KA. Implementation of the ACC/AHA guidelines for preoperative cardiac risk assessment in a general medicine preoperative clinic: improving efficiency and preserving outcomes. *Cardiology*. 2005;103(1):24-9.

Beattie WS, Abdelnaem E, Wijeyesundera DN, Buckley DN. A meta-analytic comparison of preoperative stress echocardiography and nuclear scintigraphy imaging. *Anesth Analg*. 2006 Jan;102(1):8-16.

Raux M, Godet G, Isnard R, Mergoni P, Goarin JP, Bertrand M, Fleron M, Coriat P, Riou B. Low negative predictive value of dobutamine stress echocardiography before abdominal aortic surgery. *Br J Anaesth*. 2006 Dec;97(6):770-6.

#### GLOMERULAR FILTRATION RATE TESTING

Berg UB. Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. *Nephrol Dial Transplant*. 2006 Sep;21(9):2577-82.

John GT, Fleming JJ, Talaulikar GS, Selvakumar R, Thomas PP, Jacob CK. Measurement of renal function in kidney donors using serum cystatin C and beta(2)-microglobulin. *Ann Clin Biochem*. 2003 Nov;40(Pt 6):656-8.

Textor SC, Taler SJ, Larson TS, Prieto M, Griffin M, Gloor J, Nyberg S, Velosa J, Schwab T, Stegall M. Blood pressure evaluation among older living kidney donors. *J Am Soc Nephrol*. 2003 Aug;14(8):2159-67.

Shokeir AA, Gad HM, el-Diasty T. Role of radioisotope renal scans in the choice of nephrectomy side in live kidney donors. *J Urol*. 2003 Aug;170(2 Pt 1):373-6.

Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. *Ann Intern Med*. 2004 Dec 21;141(12):929-37. Summary for patients in: *Ann Intern Med*. 2004 Dec 21;141(12):140.

Rook M, Hofker HS, van Son WJ, Homan van der Heide JJ, Ploeg RJ, Navis GJ. Predictive capacity of pre-donation GFR and renal reserve capacity for donor renal function after living kidney donation. *Am J Transplant*. 2006 Jul;6(7):1653-9.

Gonwa TA, Atkins C, Zhang YA, Parker TF, Hunt JM, Lu CY, White MG. Glomerular filtration rates in persons evaluated as living-related donors--are our standards too high? *Transplantation*. 1993 May;55(5):983-5.

#### OBESITY AND KIDNEY DISEASE

Rea DJ, Heimbach JK, Grande JP, Textor SC, Taler SJ, Prieto M, Larson TS, Cosio FG, Stegall MD. Glomerular volume and renal histology in obese and non-obese living kidney donors. *Kidney Int*. 2006 Nov;70(9):1636-41.

Heimbach JK, Taler SJ, Prieto M, Cosio FG, Textor SC, Kudva YC, Chow GK, Ishitani MB, Larson TS, Stegall MD. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. *Am J Transplant*. 2005 May;5(5):1057-6.

Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, Diaz-Gonzalez R, Leiva O, Praga M. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. *Kidney Int.* 2005 Jul;68(1):263-70.

Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Diaz-Gonzalez R, Rodicio JL. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. *Kidney Int.* 2000 Nov;58(5):2111-8.

Ferreira-Filho SR, da Silva Passos L, Ribeiro MB. Corporeal weight gain and metabolic syndrome in living kidney donors after nephrectomy. *Transplant Proc.* 2007 Mar;39(2):403-6.

Praga M, Morales E. Obesity, proteinuria and progression of renal failure. *Curr Opin Nephrol Hypertens.* 2006 Sep;15(5):481-6.

Gonzalez E, Gutierrez E, Morales E, Hernandez E, Andres A, Bello I, Diaz-Gonzalez R, Leiva O, Praga M. Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. *Kidney Int.* 2005 Jul;68(1):263-70.

Ferreira-Filho SR, da Silva Passos L, Ribeiro MB. Corporeal weight gain and metabolic syndrome in living kidney donors after nephrectomy. *Transplant Proc.* 2007 Mar;39(2):403-6.

Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. *Ann Intern Med.* 2006 Jan 3;144(1):21-8. Summary for patients in: [Ann Intern Med.](#) 2006 Jan 3;144(1):I28

Nguyen S, Hsu CY. Excess weight as a risk factor for kidney failure. *Curr Opin Nephrol Hypertens.* 2007 Mar;16(2):71-6. Review.

Iseki K. Body mass index and the risk of chronic renal failure: the Asian experience. *Contrib Nephrol.* 2006;151:42-56.

Speckman RA, McClellan WM, Volkova NV, Jurkowitz CT, Satko SG, Schoolwerth AC, Freedman BI. Obesity is associated with family history of ESRD in incident dialysis patients. *Am J Kidney Dis.* 2006 Jul;48(1):50-8.

Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk for chronic renal failure. *J Am Soc Nephrol.* 2006 Jun;17(6):1695-702.

Kramer HJ, Saranathan A, Luke A, Durazo-Arvizu RA, Guichan C, Hou S, Cooper R. Increasing body mass index and obesity in the incident ESRD population. *J Am Soc Nephrol.* 2006 May;17(5):1453-9.

Ito K, Nakashima J, Hanawa Y, Oya M, Ohigashi T, Marumo K, Murai M. The prediction of renal function 6 years after unilateral nephrectomy using preoperative risk factors. *J Urol.* 2004 Jan;171(1):120-5.

Nielsen FS, Gall MA, Parving HH. Acquired oligonephropathy and diabetic nephropathy. *Am J Kidney Dis.* 1995 Dec;26(6):898-903.

Schmitz A, Christensen CK, Christensen T, Solling K. No microalbuminuria or other adverse effects of long-standing hyperfiltration in humans with one kidney. *Am J Kidney Dis.* 1989 Feb;13(2):131-6.

Lima DX, Petroianu A, Hauter HL. Quality of life and surgical complications of kidney donors in the late post-operative period in Brazil. *Nephrol Dial Transplant*. 2006 Nov;21(11):3238-42. Epub 2006 Aug 1

Demir E, Balal M, Paydas S, Sertdemir Y, Erken U. Dyslipidemia and weight gain secondary to lifestyle changes in living renal transplant donors. *Transplant Proc*. 2005 Dec;37(10):4176-9.

#### PREOPERATIVE COAGULATION TESTING

Abbasi S, Khan FA. Effect of pre-operative coagulation testing on intra-operative transfusion requirements in surgical patients. *J Coll Physicians Surg Pak*. 2005 Jun;15(6):319-22

Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. *Ann Intern Med*. 2003 Feb 4;138(3):W15-24. Review.

Eisert S, Hovermann M, Bier H, Gobel U. Preoperative screening for coagulation disorders in children undergoing adenoidectomy (AT) and tonsillectomy (TE): does it prevent bleeding complications? *Klin Padiatr*. 2006 Nov-Dec;218(6):334-9.

Ng KF, Lai KW, Tsang SF. Value of preoperative coagulation tests: reappraisal of major noncardiac surgery. *World J Surg*. 2002 May;26(5):515-20.

Token A, Shvarts S, Perry ZH, Doron Y, Reuveni H. Clinical guidelines, defensive medicine, and the physician between the two. *Am J Otolaryngol*. 2004 Jul-Aug;25(4):245-50.

Wahlander K, Larson G, Lindahl TL, Andersson C, Firison L, Gustafsson D, Bylock A B.I. E: Factor V Leiden (G1691A and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. *Thromb Haemost* 87:580-585, 2002.

De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G: The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. *N Engl J Med*. 1999; 341:801-806.

Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004 Sep;126(3 Suppl):338S-400S. Review

#### MICROALBUMINURIA – RENAL DISEASE AND OTHER COMPLICATIONS

Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update. *J Clin Hypertens (Greenwich)*. 2007 Mar;9(3):196-200.

Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. *Am J Kidney Dis*. 2006 Jun;47(6):927-46.

Hao Z, Konta T, Takasaki S, Abiko H, Ishikawa M, Takahashi T, Ikeda A, Ichikawa K, Kawata S, Kato T, Kubota I. The association between microalbuminuria and metabolic syndrome in the general population in Japan: the Takahata study. *Intern Med*. 2007;46(7):341-6.

Bang H, Vupputuri S, Shoham DA, Klemmer PJ, Falk RJ, Mazumdar M, Gipson D, Colindres RE, Kshirsagar AV. SCreening for Occult RENal Disease (SCORED): a simple prediction model for chronic kidney disease. *Arch Intern Med*. 2007 Feb 26;167(4):374-81.

Brantsma AH, Athobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? *J Am Soc Nephrol.* 2007 Feb;18(2):637-45.

Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. *Kidney Int.* 2007 Jan;71(2):159-66.

#### URIC ACID

Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. *Cleve Clin J Med.* 2006 Dec;73(12):1059-64.

Short RA, Tuttle KR. Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: a statistical modeling perspective. *Semin Nephrol.* 2005 Jan;25(1):25-31. Review.

Shultis WA, Weil EJ, Looker HC, Curtis JM, Shlossman M, Genco RJ, Knowler WC, Nelson RG. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes. *Diabetes Care.* 2007 Feb;30(2):306-11.

#### CANCER TRANSMISSION FROM DONORS

Neipp M, Schwarz A, Pertschy S, Klempnauer J, Becker T. Accidental transplantation of a kidney with a cystic renal cell carcinoma following living donation: management and 1 yr follow-up. *Clin Transplant.* 2006 Mar-Apr;20(2):147-50.

Greco AJ, Baluarte JH, Meyers KE, Sellers MT, Suchi M, Biegel JA, Kaplan BS. Chromophobe renal cell carcinoma in a pediatric living-related kidney transplant recipient. *Am J Kidney Dis.* 2005 Jun;45(6):e105-8.

Weigert AL, Pires A, Adragao T, Cardoso E, Cardoso C, Sancho R, Trindade H, Pimentel MS, Casqueiro A, Machado D. Human herpes virus-8 serology and DNA analysis in recipients of renal allografts showing Kaposi's sarcoma and their respective donors. *Transplant Proc.* 2004 May;36(4):902-4.

Birkeland SA, Storm HH. Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. *Transplantation.* 2002 Nov 27;74(10):1409-13.

Nocera A, Corbellino M, Valente U, Barocci S, Torre F, De Palma R, Sementa A, Traverso GB, Icardi A, Fontana I, Arcuri V, Poli F, Cagetti P, Moore P, Parravicini C. Posttransplant human herpes virus 8 infection and seroconversion in a Kaposi's sarcoma affected kidney recipient transplanted from a human herpes virus 8 positive living related donor. *Transplant Proc.* 1998 Aug;30(5):2095-6.

Penn I. Transmission of cancer from organ donors. *Ann Transplant.* 1997;2(4):7-12.

Andrews CA, Shah KV, Daniel RW, Hirsch MS, Rubin RH. A serological investigation of BK virus and JC virus infections in recipients of renal allografts. *J Infect Dis.* 1988 Jul;158(1):176-81.

#### INFECTION

Nocera A, Corbellino M, Valente U, Barocci S, Torre F, De Palma R, Sementa A, Traverso GB, Icardi A, Fontana I, Arcuri V, Poli F, Cagetti P, Moore P, Parravicini C. Posttransplant human herpes virus 8 infection and seroconversion in a Kaposi's sarcoma affected kidney recipient transplanted from a human herpes virus 8 positive living related donor. *Transplant Proc.* 1998 Aug;30(5):2095-6.

Gallegos-Orozco JF, Vargas HE. Should antihepatitis B virus core positive or antihepatitis C virus core positive subjects be accepted as organ donors for liver transplantation? *J Clin Gastroenterol.* 2007 Jan;41(1):66-74. Review.

Obed A, Schnitzbauer AA, Bein T, Lehn N, Linde HJ, Schlitt HJ. Fatal pneumonia caused by Pantone-Valentine Leucocidine-positive methicillin-resistant *Staphylococcus aureus* (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. *Transplantation.* 2006 Jan 15;81(1):121-4.

Fan ST. Transmission of infection from live donor to recipient. *Transplantation.* 2006 Jan 15;81(1):16.

Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. *Liver Int.* 2005 Dec;25(6):1169-74.

Judas F, Teixeira L, Proenca A. Coimbra University Hospitals' bone and tissue bank: twenty-two years of experience. *Transplant Proc.* 2005 Jul-Aug;37(6):2799-801.

Lee KW, Lee DS, Lee HH, Kim SJ, Joh JW, Seo JM, Choe YH, Lee SK. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. *Transplant Proc.* 2004 Oct;36(8):2311-2.

Marcelin AG, Calvez V, Dussaix E. KSHV after an organ transplant: should we screen? *Curr Top Microbiol Immunol.* 2007;312:245-62.

Fabrizi F, Bunnapradist S, Lunghi G, Martin P. Transplantation of kidneys from HCV-positive donors: a safe strategy? *J Nephrol.* 2003 Sep-Oct;16(5):617-25. Review.

Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, Pham SM, Zaki S, Lanciotti RS, Lance-Parker SE, DiazGranados CA, Winkquist AG, Perlino CA, Wiersma S, Hillyer KL, Goodman JL, Marfin AA, Chamberland ME, Petersen LR; West Nile Virus in Transplant Recipients Investigation Team. Transmission of West Nile virus from an organ donor to four transplant recipients. *N Engl J Med.* 2003 May 29;348(22):2196-203.

Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage. *J Nephrol.* 2002 Nov-Dec;15(6):605-13. Review.

Natov SN. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus). *Transpl Infect Dis.* 2002 Sep;4(3):124-31. Review.

Natov SN, Pereira BJ. Transmission of viral hepatitis by kidney transplantation: donor evaluation and transplant policies (Part 1: hepatitis B virus). *Transpl Infect Dis.* 2002 Sep;4(3):117-23. Review

Tanphaichitr NT, Brennan DC. Infectious complications in renal transplant recipients. *Adv Ren Replace Ther.* 2000 Apr;7(2):131-46. Review.

Fischer L, Sterneck M, Claus M, Costard-Jackle A, Fleischer B, Herbst H, Rogiers X, Broelsch CE. Transmission of malaria tertiana by multi-organ donation. Clin Transplant. 1999 Dec;13(6):491-5. Review.

Green M, Avery R. Screening of donor and recipient prior to solid organ transplant. Am J Transplant 2004; 4 (Suppl 10): 10-20.

Hernandez-Hernandez E, Alberu J, Gonzalez-Michaca L, Bobadilla-del Valle M, Correa-Rotter R, Sifuentes-Osornio J. Screening for tuberculosis in the study of the living renal donor in a developing country. Transplantation. 2006 Jan 27;81(2):290-2.

Khosroshahi HT, Shoja EA, Beiglu LG, Hassan AP. Tuberculin testing of kidney allograft recipients and donors before transplantation. Transplant Proc. 2006 Sep;38(7):1982-4.

Shankar MS, Aravindan AN, Sohal PM, Kohli HS, Sud K, Gupta KL, Sakhuja V, Jha V. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant. 2005 Dec;20(12):2720-4. Epub 2005 Sep 2

Shultis WA, Weil EJ, Looker HC, Curtis JM, Shlossman M, Genco RJ, Knowler WC, Nelson RG. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes. Diabetes Care. 2007 Feb;30(2):306-11.

#### RENOVASCULAR DISEASE – FIBROMUSCULAR DYSPLASIA AND ARTERIOSCLEROSIS

Neymark E, LaBerge JM, Hirose R, Melzer JS, Kerlan RK, Jr., Wilson MW, Gordon RL: Arteriographic detection of renovascular disease in potential renal donors: incidence and effect on donor surgery. Radiology 214:755-760, 2000.

Cragg AH, Smith TP, Thompson BH, Maroney TP, Stanson AW, Shaw GT, Hunter DW, Cochran ST: Incidental fibromuscular dysplasia in potential renal donors: Long-term clinical follow-up. Radiology 172:145-147, 1989.

Andreoni KA, Weeks SM, Gerber DA, Fair JH, Mauro MA, McCoy L, Scott L, Johnson MW: Incidence of donor renal fibromuscular dysplasia: does it justify routine angiography? Transplantation 73:1112-1116., 2002.

Parasuraman R, Attallah N, Venkat KK, Yoshida A, Abouljoud M, Khanal S, Greenbaum A. Rapid progression of native renal artery fibromuscular dysplasia following kidney donation. Am J Transplant. 2004 Nov;4(11):1910-4.

Indudhara R, Kenney, Bueschen AJ, Burns JR: Live donor nephrectomy in patients with fibromuscular dysplasia of the renal arteries. J Urol 162:678-681., 1999.

Serrano DP, Flechner SM, Modlin CS, Strem SB, Goldfarb DA, Novick AC: The use of kidneys from living donors with renal vascular disease: expanding the donor pool. J Urol 157:1587-1591, 1997.

Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL, Strandness DE, Jr.: A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertens 9:1055-1061, 1996.

Pillay WR, Kan YM, Crinnion JN, Wolfe JH: Prospective multicentre study of the natural history of atherosclerotic renal artery stenosis in patients with peripheral vascular disease. *Br J Surg* 89:737-740, 2002.

Edwards MS, Hansen KJ, Craven TE, Bleyer AJ, Burke GL, Levy PJ, Dean RH: Associations between renovascular disease and prevalent cardiovascular disease in the elderly: a population-based study. *Vasc Endovascular Surg* 38:25-35, 2004.

Zierler RE, Bergelin RO, Polissar NL, Beach KW, Caps MT, Cantwell-Gab K, Davidson RC, Strandness DE, Jr.: Carotid and lower extremity arterial disease in patients with renal artery atherosclerosis. *Arch Intern Med* 158:761-767, 1998.

#### CARDIAC VALVE DISEASE

Vitarelli A, Morichetti MC, Conde Y, Cimino E, D'Orazio S, Stellato S, Padella V, Caranci F, Battaglia D. ASSESSMENT OF SEVERITY IN AORTIC STENOSIS-INCREMENTAL VALUE OF ENDOCARDIAL FUNCTION PARAMETERS COMPARED WITH STANDARD INDEXES. *Ultrasound Med Biol*. 2007 Apr 26;

Yap SC, Kouwenhoven GC, Takkenberg JJ, Galema TW, Meijboom FJ, van Domburg R, Simoons ML, Roos-Hesselink JW. Congenital aortic stenosis in adults: Rate of progression and predictors of clinical outcome. *Int J Cardiol*. 2007 Feb 7

Pai RG, Kapoor N, Bansal RC, Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. *Ann Thorac Surg*. 2006 Dec;82(6):2116-22.

Rinkevich D, Lessick J, Mutlak D, Markiewicz W, Reisner SA. Natural history of moderate mitral valve stenosis. *Isr Med Assoc J*. 2003 Jan;5(1):15-8.

Chirillo F, Salvador L, Cavallini C. Medical and surgical treatment of chronic mitral regurgitation. *J Cardiovasc Med (Hagerstown)*. 2006 Feb;7(2):96-107. Review

Avierinos JF, Gersh BJ, Melton LJ 3rd, Bailey KR, Shub C, Nishimura RA, Tajik AJ, Enriquez-Sarano M. Natural history of asymptomatic mitral valve prolapse in the community. *Circulation*. 2002 Sep 10;106(11):1355-61.

#### DONOR FOLLOW UP

Lima DX, Petroianu A, Hauter HL. Quality of life and surgical complications of kidney donors in the late post-operative period in Brazil. *Nephrol Dial Transplant*. 2006 Nov;21(11):3238-42. Epub 2006 Aug 1

McCune TR, Armata T, Mendez-Picon G, Yium J, Zabari GB, Crandall B, Spicer HG, Blanton J, Thacker LR. The Living Organ Donor Network: a model registry for living kidney donors. *Clin Transplant*. 2004;18 Suppl 12:33-8.

Clemens KK, Thiessen-Philbrook H, Parikh CR, Yang RC, Karley ML, Boudville N, Ramesh Prasad GV, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network. Psychosocial health of living kidney donors: a systematic review. *Am J Transplant*. 2006 Dec;6(12):2965-77.

Prager LM, Wain JC, Roberts DH, Ginns LC. Medical and psychologic outcome of living lobar lung transplant donors. *J Heart Lung Transplant*. 2006 Oct;25(10):1206-12.

Smith GC, Trauer T, Kerr PG, Chadban SJ. Prospective psychosocial monitoring of living kidney donors using the Short Form-36 health survey: results at 12 months. *Transplantation*. 2004 Nov 15;78(9):1384-9.

Boulware LE, Ratner LE, Troll MU, Chaudron A, Yeung E, Chen S, Klein AS, Hiller J, Powe NR. Attitudes, psychology, and risk taking of potential live kidney donors: strangers, relatives, and the general public. *Am J Transplant*. 2005 Jul;5(7):1671-80.

Heck G, Schweitzer J, Seidel-Wiesel M. Psychological effects of living related kidney transplantation - risks and chances. *Clin Transplant*. 2004 Dec;18(6):716-21.